Microfluidic Platform for Single Nucleotide Polymorphism Genotyping of the Thiopurine S-Methyltransferase Gene to Evaluate Risk for Adverse Drug Events

Abstract

Prospective clinical pharmacogenetic testing of the thiopurine S-methyltransferase gene remains to be realized despite the large body of evidence demonstrating clinical benefit for the patient and cost effectiveness for health care systems. We describe an entirely microchipbased method to genotype for common single nucleotide polymorphisms in the thiopurine S-methyltransferase gene that lead to serious adverse drug reactions for patients undergoing thiopurine therapy. Restriction fragment length polymorphism and allele-specific polymerase chain reaction have been adapted to a microfluidic chip-based polymerase chain reaction and capillary electrophoresis platform to genotype the common *2, *3A, and *3C functional alleles. In total, 80 patients being treated with thiopurines were genotyped, with 100% concordance between microchip and conventional methods. This is the first report of single nucleotide polymorphism detection using portable instrumentation and represents a significant step toward miniaturized for personalized treatment and automated point-of-care testing. (J Mol Diagn 2007, 9:521-529;

A novel method of microsatellite genotyping-by-sequencing using individual combinatorial barcoding

“…The concurrent development of single-nucleotide polymorphism (SNP) genotyping platforms (e.g. SNP-chips [ 10 , 11 ], microfluidic TaqMAN assays [ 12 ]) and the persistent problems associated with microsatellite genotyping has led to a shift from using microsatellites to SNPs as the preferred marker for genetic studies [ 13 ]. The main problems with capillary and gel-based microsatellite studies include fragment size homoplasy, poor levels of inter-laboratory calibration, the genotype not including the underlying sequence information and inherently laborious genotyping [ 14 , 15 ].…”

Detection of Low-Abundance KRAS Mutations in Colorectal Cancer Using Microfluidic Capillary Electrophoresis-Based Restriction Fragment Length Polymorphism Method with Optimized Assay Conditions

“…Considering these distinct advantages, RFLP has been transplanted onto this microscale platform to detect gene mutations [29]–[31]. Some groups have also established on-chip direct endonuclease digestion and electrophoresis detection systems, which demonstrated the capabilities for integration and parallel analysis and the possibility to further increase the detection speed and throughput [32], [33]. However, up to now, quite few reports focused on how to take the unique advantages of microfluidic electrophoresis to achieve highly sensitive screening for low-abundance mutants in cancer biopsies, especially those in trace clinical sample, so detection methods with high sensitivity still remains to be developed to fulfill the clinical and diagnostic utility.…”

Microsystems for personalized biomolecular diagnostics

“…An integrated microfluidic device has been presented by Chowdhury et al . 18 , which combines either restriction fragment length polymorphism analysis or allele‐specific PCR with capillary electrophoresis for identification of the three most common SNP alleles associated with TPMT deficiency. The microfluidic device was partnered with a control system which was used to supply thermal cycling, electrokinetic movement and detection components.…”